WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-10 07:48 am Sale |
2022-01-31 | 13G | Aligos Therapeutics, Inc. ALGS |
WELLINGTON MANAGEMENT CO LLP | 52,173 3.060% |
-90,306 (-63.38%) |
Filing |
| 2022-02-04 09:12 am Sale |
2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
WELLINGTON MANAGEMENT CO LLP | 142,479 8.360% |
-14,625 (-9.31%) |
Filing |
| 2021-01-11 09:10 am Purchase |
2020-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
WELLINGTON MANAGEMENT CO LLP | 157,104 10.300% |
157,104 (New Position) |
Filing |